Conference Call with Poly Medicure Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Healthcare Supplies company Poly Medicure announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations increased by 17% in Q4FY25 to Rs 440.8 crore, compared to Q4FY24 Rs 378.1 crore; FY25 revenue growth stood at 21%. EBITDA grew by 24% in Q4FY25 on a YoY basis, reflecting our strong earnings capability from core operations. The EBITDA margins improved by 160BPS to 27% in Q4FY25. Profit After Tax (PAT) increased by 34% in Q4FY25 to Rs 91.8 crore compared to Q4FY24 Rs 68.4 crore, ; PAT margin expanded by almost 270BPS to 21% in Q4FY25. FY25 Financial Highlights: Export revenue for FY25 increased by 24% YoY, driven by continued strong performance in key international markets. Geopolitical tensions and tariff war creating short term demand uncertainty in certain export markets. The domestic quarterly and yearly revenue growth was 24% and 19% respectively on a YoY basis, domestic revenue growth has shown strong traction as the year progressed. The balance sheet position remains strong with liquidity position of Rs 1220 crore as at March 25. Adjusted RoCE was 23.4% for FY25 as compared to 23% in the corresponding previous financial year. Incurred a CAPEX of Rs 325 crore in FY25 reflecting our commitment to create adequate infrastructure to capture future growth opportunities in the sector. Himanshu Baid, Managing Director, Poly Medicure, said: We are extremely pleased with our continued growth in the business in the Q4 and FY25. Our margins continue to expand at higher scale of operations and that gives us immense confidence to keep investing capital to create additional manufacturing capacities. FY25 has been a transformative year for Polymed as we commercialised two new divisions, Cardiology and Critical Care. Our renal division continues to grow from strength to strength while the core infusion therapy consolidates its leadership position in clinically driven segments. The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. We believe that India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains. Our investment in 3 new plants is going on strongly, which we believe positions us very strongly to achieve the significant growth opportunities that lie in front of us. Result PDF
Conference Call with Poly Medicure Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Supplies company Poly Medicure announced Q3FY25 results Revenue: Rs 424.2 crore compared to Rs 339.6 crore during Q3FY24, change 24.9%. EBITDA: Rs 116.3 crore compared to Rs 90.9 crore during Q3FY24, change 27.9%. EBITDA margin: 27.4% for Q3FY25. PAT: Rs 85.2 crore compared to Rs 65.0 crore during Q3FY24, change 31.1%. Net Cash: Rs 1074.3 for Q3FY25. ROCE: 23.9% for Q3FY25. Result PDF